140 related articles for article (PubMed ID: 37875524)
1. Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
Bodet-Milin C; Morvant C; Carlier T; Frecon G; Tournilhac O; Safar V; Kraeber-Bodere F; Le Gouill S; Macintyre E; Bailly C
Sci Rep; 2023 Oct; 13(1):18177. PubMed ID: 37875524
[TBL] [Abstract][Full Text] [Related]
2. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S; Beldi-Ferchiou A; Alcantara M; Cacheux V; Safar V; Burroni B; Guidez S; Gastinne T; Canioni D; Thieblemont C; Maisonneuve H; Bodet-Milin C; Houot R; Oberic L; Bouabdallah K; Bescond C; Damaj G; Jaccard A; Daguindau N; Moreau A; Tilly H; Ribrag V; Delfau-Larue MH; Hermine O; Macintyre E
Lancet Haematol; 2020 Nov; 7(11):e798-e807. PubMed ID: 32971036
[TBL] [Abstract][Full Text] [Related]
3. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Clinical Impact of Staging
Albano D; Ferro P; Bosio G; Fallanca F; Re A; Tucci A; Maria Ferreri AJ; Angelillo P; Gianolli L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e457-e464. PubMed ID: 31129112
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
6.
Li H; Xu C; Xin B; Zheng C; Zhao Y; Hao K; Wang Q; Wahl RL; Wang X; Zhou Y
Theranostics; 2019; 9(16):4730-4739. PubMed ID: 31367253
[No Abstract] [Full Text] [Related]
7. Application of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in mantle cell lymphoma.
Yang S; Fu L; AbuduRxiti M; Wu J; Wang Q; Qin Y; Zou X; Li H
Nucl Med Commun; 2020 May; 41(5):477-484. PubMed ID: 32168265
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow segmentation and radiomics analysis of [
Milara E; Gómez-Grande A; Tomás-Soler S; Seiffert AP; Alonso R; Gómez EJ; Martínez-López J; Sánchez-González P
Comput Methods Programs Biomed; 2022 Oct; 225():107083. PubMed ID: 36044803
[TBL] [Abstract][Full Text] [Related]
9. Radiomics analysis of bone marrow biopsy locations in [
Milara E; Alonso R; Masseing L; Seiffert AP; Gómez-Grande A; Gómez EJ; Martínez-López J; Sánchez-González P
Phys Eng Sci Med; 2023 Jun; 46(2):903-913. PubMed ID: 37155114
[TBL] [Abstract][Full Text] [Related]
10.
Albano D; Treglia G; Gazzilli M; Cerudelli E; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):422-430. PubMed ID: 32169480
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
12. Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma.
Morgan R; Perry M; Kwak J; Jensen A; Kamdar M
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):731-736. PubMed ID: 30075973
[TBL] [Abstract][Full Text] [Related]
13. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.
Mayerhoefer ME; Riedl CC; Kumar A; Gibbs P; Weber M; Tal I; Schilksy J; Schöder H
Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2760-2769. PubMed ID: 31286200
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Bodet-Milin C; Touzeau C; Leux C; Sahin M; Moreau A; Maisonneuve H; Morineau N; Jardel H; Moreau P; Gallazini-Crépin C; Gries P; Gressin R; Harousseau JL; Mohty M; Moreau P; Kraeber-Bodere F; Le Gouill S
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1633-42. PubMed ID: 20428863
[TBL] [Abstract][Full Text] [Related]
15. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
16. [
Vergote VKJ; Verhoef G; Janssens A; Woei-A-Jin FJSH; Laenen A; Tousseyn T; Dierickx D; Deroose CM
Leuk Lymphoma; 2023 Jan; 64(1):161-170. PubMed ID: 36223113
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography in mantle cell lymphoma.
Brepoels L; Stroobants S; De Wever W; Dierickx D; Vandenberghe P; Thomas J; Mortelmans L; Verhoef G; De Wolf-Peeters C
Leuk Lymphoma; 2008 Sep; 49(9):1693-701. PubMed ID: 18798104
[TBL] [Abstract][Full Text] [Related]
18. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
20. Bone Marrow and Tumor Radiomics at
Mattonen SA; Davidzon GA; Benson J; Leung ANC; Vasanawala M; Horng G; Shrager JB; Napel S; Nair VS
Radiology; 2019 Nov; 293(2):451-459. PubMed ID: 31526257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
